UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1-80 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/121,798	07/23/1998	ROBERT BRIDENBAUGH	213-0012US	3701
	7590 10/17/200 LLO LUTSCH RUTHI	EXAMINER		
20333 SH 249, SUITE 600			VOGEL, NANCY TREPTOW	
HOUSTON, TX 77070			ART UNIT	PAPER NUMBER
			1636	
			MAIL DATE	DELIVERY MODE
			10/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	09/121,798	BRIDENBAUGH ET AL.			
Office Action Summary	Examiner	Art Unit			
	NANCY VOGEL	1636			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period v Failure to reply within the set or extended period for reply will, by statute. Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA 36(a). In no event, however, may a repl vill apply and will expire SIX (6) MONTH , cause the application to become ABAN	ATION. y be timely filed S from the mailing date of this communication. IDONED (35 U.S.C. § 133).			
Status					
 Responsive to communication(s) filed on <u>25 June 2008</u>. This action is FINAL. 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213. 					
Disposition of Claims					
4) Claim(s) 23-26 and 28-47 is/are pending in the 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 23-26 and 28-47 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine	wn from consideration. r election requirement. r.	the Evaminer			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) ☐ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☑ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 6/25/08		nmary (PTO-413) Mail Date rmal Patent Application			

DETAILED ACTION

Claims 23-26, 28-47 are pending in the case.

Receipt of the Information Disclosure Statement on 6/25/08 is acknowledged. The reference which is struck through has not been received. IT is noted that a document has been received which does not appear on the Information Disclosure statement, which appears to be opposition documents from two companies, i.e. PowderJect Vaccines, and Novartis Vaccines and Diagnostics.

Any rejection of record in the previous action not addressed in this office action is withdrawn.

The following is a new rejection:

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 23-26 and 28-47 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of compete or partial structure, physical and/or

Art Unit: 1636

chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the claims are directed to a method of removing endotoxin from a plasmid DNA solution comprising a step of filtering through a series of filters including a glass fiber filter and a nylon filter. While the specification discloses that filtration through a .2µm filter from certain vendors (Pall-Filtron, Sartorius and Gelman), made of glass or nylon, removes endotoxin and results in minimal nucleic acid loss (page 15), there is no disclosure of filters other than this size and these vendors that would have this property of removing endotoxins without nucleic acid loss. There is no description of the identifying characteristics for recognizing that a particular filter from a particular manufacturer will have the claimed property of removing endotoxins. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus, which includes any glass or nylon filter having the claimed property. Therefore, the inventor, at the time the application was filed was not in possession of the broad genus comprising methods of removing endotoxin from a plasmid DNA solution comprising filtration through any glass or nylon filter, needed to practice the invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANCY VOGEL whose telephone number is (571)272-0780. The examiner can normally be reached on 7:00 - 3:30, Monday - Friday.

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NANCY VOGEL/ Primary Examiner, Art Unit 1636

NV 10/9/08